Details of the Drug

General Information of Drug (ID: DMIT8LX)

Drug Name
Fluphenazine
Synonyms
FLUPHENAZINE; Triflumethazine; Fluorophenazine; Fluorphenazine; Fluorfenazine; Siqualon; Elinol; 69-23-8; Phthorphenazine; Vespazine; Ftorphenazine; Siqualine; Sevinol; Pacinol; Fluphenazinum; Flufenazina; Prolixin; Flufenazin; Dapotum; Flufenazina [DCIT]; Yespazine; SQ 4918; Fluphenazine [INN:BAN]; Moditen (Tabl or elixir); Fluphenazinum [INN-Latin]; 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; UNII-S79426A41Z; HSDB 3334; Dapotum; Prolixine; Fluphenazine hydrochloride; Moditen Hcl; Permitil Concentrate; Prolixin Concentrate; S94; Anatensol (TN); Apo-Fluphenazine; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Enanthate (TN); Fludecate (TN); Flunanthate (TN); Fluphenazine (INN); Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen Enanthate Injection (TN); Omca (TN); Permitil (TN); Prolixin (TN); Sediten (TN); Selecten (TN); Sevinol (TN); Sinqualone (TN); Trancin (TN)
Indication
Disease Entry ICD 11 Status REF
Psychotic disorder 6A20-6A25 Approved [1]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [2]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [3]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 437.5
Logarithm of the Partition Coefficient (xlogp) 4.4
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 9.7 mL/min/kg [5]
Elimination
0.1% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 12.3 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.65238 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.04% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.9 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.031 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Tardive dyskinesia Not Available DRD3 OT0OFFKB [7]
Tardive dyskinesia Not Available DRD4 OTAJTO7N [7]
Chemical Identifiers
Formula
C22H26F3N3OS
IUPAC Name
2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol
Canonical SMILES
C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
InChI
InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
InChIKey
PLDUPXSUYLZYBN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3372
ChEBI ID
CHEBI:5123
CAS Number
69-23-8
DrugBank ID
DB00623
TTD ID
D0P5SA
VARIDT ID
DR00658
INTEDE ID
DR0723
ACDINA ID
D00285
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Modulator [8]
HUMAN clathrin-mediated endocytosis (RME) TTAIY2U . Inhibitor [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5-hydroxytryptamine receptor 2A (HTR2A) OTWXJX0M 5HT2A_HUMAN Protein Interaction/Cellular Processes [11]
5-hydroxytryptamine receptor 2C (HTR2C) OT6H8DE0 5HT2C_HUMAN Protein Interaction/Cellular Processes [11]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Gene/Protein Processing [12]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Gene/Protein Processing [12]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Gene/Protein Processing [12]
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Gene/Protein Processing [12]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [12]
D(2) dopamine receptor (DRD2) OTBLXKEG DRD2_HUMAN Protein Interaction/Cellular Processes [11]
D(3) dopamine receptor (DRD3) OT0OFFKB DRD3_HUMAN Drug Response [7]
D(4) dopamine receptor (DRD4) OTAJTO7N DRD4_HUMAN Drug Response [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Psychotic disorder
ICD Disease Classification 6A20-6A25
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 1B receptor (HTR1B) DTT HTR1B 3.68E-03 0.16 0.92
P-glycoprotein 1 (ABCB1) DTP P-GP 7.83E-01 4.69E-02 1.89E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fluphenazine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Fluphenazine and Levomepromazine. Psychotic disorder [6A20-6A25] [13]
Coadministration of a Drug Treating the Disease Different from Fluphenazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Fluphenazine and Ivosidenib. Acute myeloid leukaemia [2A60] [14]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Midostaurin. Acute myeloid leukaemia [2A60] [15]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Idarubicin. Acute myeloid leukaemia [2A60] [15]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Daunorubicin. Acute myeloid leukaemia [2A60] [16]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Gilteritinib. Acute myeloid leukaemia [2A60] [17]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Fluphenazine and Oliceridine. Acute pain [MG31] [18]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Fluphenazine and Scopolamine. Addictive disorder [6C50-6C5Z] [13]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Fluphenazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [19]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Fluphenazine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [19]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Fluphenazine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [13]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Fluphenazine and Memantine. Alzheimer disease [8A20] [13]
Galantamine DMEO794 Moderate Antagonize the effect of Fluphenazine when combined with Galantamine. Alzheimer disease [8A20] [20]
Rivastigmine DMG629M Moderate Antagonize the effect of Fluphenazine when combined with Rivastigmine. Alzheimer disease [8A20] [20]
Donepezil DMIYG7Z Moderate Antagonize the effect of Fluphenazine when combined with Donepezil. Alzheimer disease [8A20] [20]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Fluphenazine and Metronidazole. Amoebiasis [1A36] [21]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Fluphenazine and Isosorbide dinitrate. Anal fissure/fistula [DB50] [22]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Fluphenazine and Trimethaphan. Aneurysm/dissection [BD50] [23]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Ivabradine. Angina pectoris [BA40] [24]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Fluphenazine and Bepridil. Angina pectoris [BA40] [15]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Fluphenazine and Dronedarone. Angina pectoris [BA40] [15]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Fluphenazine and Amyl nitrite. Angina pectoris [BA40] [22]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Fluphenazine and Nifedipine. Angina pectoris [BA40] [22]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Fluphenazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [25]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Cilostazol. Arterial occlusive disease [BD40] [15]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Posaconazole. Aspergillosis [1F20] [15]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Levalbuterol. Asthma [CA23] [26]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Terbutaline. Asthma [CA23] [27]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Pirbuterol. Asthma [CA23] [27]
Ephedrine DMMV0KW Moderate Antagonize the effect of Fluphenazine when combined with Ephedrine. Asthma [CA23] [28]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Formoterol. Asthma [CA23] [27]
Lisdexamfetamine DM6W8V5 Moderate Antagonize the effect of Fluphenazine when combined with Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [28]
Desipramine DMT2FDC Moderate Increased plasma concentrations of Fluphenazine and Desipramine due to competitive inhibition of the same metabolic pathway. Attention deficit hyperactivity disorder [6A05] [29]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Ofloxacin. Bacterial infection [1A00-1C4Z] [30]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Clarithromycin. Bacterial infection [1A00-1C4Z] [15]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Fluphenazine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [15]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Fluphenazine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [30]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Levofloxacin. Bacterial infection [1A00-1C4Z] [30]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [15]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Telithromycin. Bacterial infection [1A00-1C4Z] [15]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Retigabine. Behcet disease [4A62] [15]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Fluphenazine and Cariprazine. Bipolar disorder [6A60] [13]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Fluphenazine and Loperamide. Bowel habit change [ME05] [31]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Eribulin. Breast cancer [2C60-2C6Y] [15]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Lapatinib. Breast cancer [2C60-2C6Y] [15]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Tamoxifen. Breast cancer [2C60-2C6Y] [15]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [32]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Fluphenazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [33]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [27]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [26]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Fluphenazine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [33]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [27]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Fluphenazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [33]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [27]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [27]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Fluphenazine and Dihydrocodeine. Chronic pain [MG30] [34]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Fluphenazine and Olopatadine. Conjunctiva disorder [9A60] [35]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Halothane. Corneal disease [9A76-9A78] [15]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Sevoflurane. Corneal disease [9A76-9A78] [15]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Fluphenazine and Alfentanil. Corneal disease [9A76-9A78] [18]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Fluphenazine and Remifentanil. Corneal disease [9A76-9A78] [18]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Probucol. Coronary atherosclerosis [BA80] [15]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Clofazimine. Crohn disease [DD70] [36]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Fluphenazine and Mifepristone. Cushing syndrome [5A70] [15]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Fluphenazine and Pasireotide. Cushing syndrome [5A70] [15]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Osilodrostat. Cushing syndrome [5A70] [24]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Fluphenazine and Cyclandelate. Dementia [6D80-6D8Z] [22]
Trimipramine DM1SC8M Moderate Increased plasma concentrations of Fluphenazine and Trimipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [29]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Fluphenazine and Cyclobenzaprine. Depression [6A70-6A7Z] [13]
Paroxetine DM5PVQE Moderate Decreased metabolism of Fluphenazine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [37]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Fluphenazine and Selegiline. Depression [6A70-6A7Z] [38]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Fluphenazine and Isocarboxazid. Depression [6A70-6A7Z] [38]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Fluphenazine and Escitalopram. Depression [6A70-6A7Z] [15]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Fluphenazine and Tranylcypromine. Depression [6A70-6A7Z] [38]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Fluphenazine and OPC-34712. Depression [6A70-6A7Z] [13]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Fluphenazine and Phenelzine. Depression [6A70-6A7Z] [38]
Clomipramine DMINRKW Moderate Increased plasma concentrations of Fluphenazine and Clomipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [29]
Doxepin DMPI98T Moderate Increased plasma concentrations of Fluphenazine and Doxepin due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [29]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Fluphenazine and Maprotiline. Depression [6A70-6A7Z] [13]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Fluphenazine and Esketamine. Depression [6A70-6A7Z] [21]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Fluphenazine and Nitroglycerin. Diabetic foot ulcer [BD54] [22]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Fluphenazine and Mepenzolate. Digestive system disease [DE2Z] [13]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Fluphenazine and Oxybutynine. Discovery agent [N.A.] [13]
Tetrabenazine DMYWQ0O Major Additive antidopaminergic effects by the combination of Fluphenazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [39]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Fluphenazine and Meclizine. Dizziness and giddiness [MB48] [13]
Deutetrabenazine DMUPFLI Major Additive antidopaminergic effects by the combination of Fluphenazine and Deutetrabenazine. Dystonic disorder [8A02] [40]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Fluphenazine and Ingrezza. Dystonic disorder [8A02] [41]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Fluphenazine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [42]
Stiripentol DMMSDOY Moderate Decreased metabolism of Fluphenazine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Fluphenazine when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [44]
Guanabenz DM5QWEL Moderate Additive hypotensive effects by the combination of Fluphenazine and Guanabenz. Essential hypertension [BA00] [22]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Fluphenazine and Ethacrynic acid. Essential hypertension [BA00] [23]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Fluphenazine and Phenoxybenzamine. Essential hypertension [BA00] [22]
Mecamylamine DMGQFYB Moderate Additive hypotensive effects by the combination of Fluphenazine and Mecamylamine. Essential hypertension [BA00] [22]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Fluphenazine and Nadolol. Essential hypertension [BA00] [22]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Solifenacin. Functional bladder disorder [GC50] [15]
Mirabegron DMS1GYT Moderate Decreased metabolism of Fluphenazine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [45]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Fluphenazine and Tolterodine. Functional bladder disorder [GC50] [13]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Pentamidine. Fungal infection [1F29-1F2F] [15]
Terbinafine DMI6HUW Moderate Decreased metabolism of Fluphenazine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [46]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Ketoconazole. Fungal infection [1F29-1F2F] [15]
Amphotericin B DMTAJQE Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Amphotericin B. Fungal infection [1F29-1F2F] [21]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Fluphenazine and Phentolamine. Gangrene [MC85] [22]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Fluphenazine and Propantheline. Gastric ulcer [DA60] [13]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [15]
Acetazolamide DM1AF5U Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Acetazolamide. Glaucoma [9C61] [21]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Fluphenazine when combined with Isoflurophate. Glaucoma [9C61] [47]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Fluphenazine when combined with Pilocarpine. Glaucoma [9C61] [47]
Eplerenone DMF0NQR Moderate Additive hypotensive effects by the combination of Fluphenazine and Eplerenone. Heart failure [BD10-BD1Z] [22]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Fluphenazine and Carvedilol. Heart failure [BD10-BD1Z] [22]
Chlorothiazide DMLHESP Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Chlorothiazide. Heart failure [BD10-BD1Z] [21]
Furosemide DMMQ8ZG Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Furosemide. Heart failure [BD10-BD1Z] [21]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Bumetanide. Heart failure [BD10-BD1Z] [21]
Hydroflumethiazide DMVPUQI Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [21]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Fluphenazine and Procarbazine. Hodgkin lymphoma [2B30] [38]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [48]
Cobicistat DM6L4H2 Moderate Decreased clearance of Fluphenazine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [49]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Fluphenazine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [50]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Fluphenazine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [51]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [15]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Fluphenazine and Isosorbide mononitrate. Hydrocephalus [8D64] [22]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Fluphenazine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [21]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Fluphenazine and Eprosartan. Hypertension [BA00-BA04] [22]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Fluphenazine and Acebutolol. Hypertension [BA00-BA04] [22]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Fluphenazine and Moexipril. Hypertension [BA00-BA04] [22]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Fluphenazine and Captopril. Hypertension [BA00-BA04] [22]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Fluphenazine and Penbutolol. Hypertension [BA00-BA04] [22]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Fluphenazine and Methyldopa. Hypertension [BA00-BA04] [22]
Losartan DM72JXH Moderate Additive hypotensive effects by the combination of Fluphenazine and Losartan. Hypertension [BA00-BA04] [22]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Fluphenazine and Nebivolol. Hypertension [BA00-BA04] [22]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Fluphenazine and Levamlodipine. Hypertension [BA00-BA04] [22]
Verapamil DMA7PEW Moderate Additive hypotensive effects by the combination of Fluphenazine and Verapamil. Hypertension [BA00-BA04] [22]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Fluphenazine and TAK-491. Hypertension [BA00-BA04] [22]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Fluphenazine and Fenoldopam. Hypertension [BA00-BA04] [22]
Indapamide DMGN1PW Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Indapamide. Hypertension [BA00-BA04] [21]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Fluphenazine and Trichlormethiazide. Hypertension [BA00-BA04] [22]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Fluphenazine and Diazoxide. Hypertension [BA00-BA04] [22]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Fluphenazine and Perindopril. Hypertension [BA00-BA04] [22]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Fluphenazine and Felodipine. Hypertension [BA00-BA04] [22]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Fluphenazine and Quinapril. Hypertension [BA00-BA04] [22]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Fluphenazine and Deserpidine. Hypertension [BA00-BA04] [22]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Fluphenazine and Telmisartan. Hypertension [BA00-BA04] [22]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Fluphenazine and Irbesartan. Hypertension [BA00-BA04] [22]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Fluphenazine and Hydralazine. Hypertension [BA00-BA04] [22]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Hydrochlorothiazide. Hypertension [BA00-BA04] [21]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Fluphenazine and Clevidipine butyrate. Hypertension [BA00-BA04] [22]
Fludrocortisone DMUDIR8 Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [21]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Fluphenazine caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [24]
Givosiran DM5PFIJ Moderate Decreased metabolism of Fluphenazine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [52]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Fluphenazine and Belladonna. Infectious gastroenteritis/colitis [1A40] [13]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Fluphenazine and Amantadine. Influenza [1E30-1E32] [53]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Fluphenazine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [54]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Fluphenazine and Propiomazine. Insomnia [7A00-7A0Z] [13]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Fluphenazine and ITI-007. Insomnia [7A00-7A0Z] [13]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [15]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Phenolphthalein. Irritable bowel syndrome [DD91] [15]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Fluphenazine and Clidinium. Irritable bowel syndrome [DD91] [13]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Fluphenazine and Dicyclomine. Irritable bowel syndrome [DD91] [13]
Physostigmine DM2N0TO Moderate Antagonize the effect of Fluphenazine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [20]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Fluphenazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [24]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Fluphenazine and Crizotinib. Lung cancer [2C25] [55]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Fluphenazine and Porfimer Sodium. Lung cancer [2C25] [56]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Fluphenazine and Ceritinib. Lung cancer [2C25] [15]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Fluphenazine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [57]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Fluphenazine and Osimertinib. Lung cancer [2C25] [58]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Fluphenazine and Selpercatinib. Lung cancer [2C25] [24]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Fluphenazine and Lumefantrine. Malaria [1F40-1F45] [21]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Fluphenazine and Halofantrine. Malaria [1F40-1F45] [59]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Fluphenazine and Hydroxychloroquine. Malaria [1F40-1F45] [60]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Primaquine. Malaria [1F40-1F45] [15]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Fluphenazine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [61]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Fluphenazine and Vemurafenib. Melanoma [2C30] [15]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and LGX818. Melanoma [2C30] [62]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Fluphenazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [63]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Fluphenazine and Flibanserin. Mood disorder [6A60-6E23] [64]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Fluphenazine and Panobinostat. Multiple myeloma [2A83] [65]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Fluphenazine and Thalidomide. Multiple myeloma [2A83] [66]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Siponimod. Multiple sclerosis [8A40] [21]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Fingolimod. Multiple sclerosis [8A40] [15]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Ozanimod. Multiple sclerosis [8A40] [67]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Romidepsin. Mycosis fungoides [2B01] [15]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Fluphenazine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [24]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Fluphenazine and Nilotinib. Myeloproliferative neoplasm [2A20] [15]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Dasatinib. Myeloproliferative neoplasm [2A20] [68]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Fluphenazine when combined with Dextroamphetamine. Narcolepsy [7A20] [28]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Fluphenazine and Phenindamine. Nasopharyngitis [CA00] [13]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Fluphenazine and Dimenhydrinate. Nausea/vomiting [MD90] [13]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Fluphenazine and Promethazine. Nausea/vomiting [MD90] [13]
Rolapitant DM8XP26 Moderate Decreased metabolism of Fluphenazine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [69]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Fluphenazine and Cyclizine. Nausea/vomiting [MD90] [13]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Fluphenazine and Metoclopramide. Nausea/vomiting [MD90] [70]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Granisetron. Nausea/vomiting [MD90] [15]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Ondansetron. Nausea/vomiting [MD90] [15]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Fluphenazine and Bupropion. Nicotine use disorder [6C4A] [15]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Entrectinib. Non-small cell lung cancer [2C25] [21]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Fluphenazine when combined with Phendimetrazine. Obesity [5B80-5B81] [28]
Amfepramone DM9YSNQ Moderate Antagonize the effect of Fluphenazine when combined with Amfepramone. Obesity [5B80-5B81] [28]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Fluphenazine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [71]
Benzphetamine DMIJATC Moderate Antagonize the effect of Fluphenazine when combined with Benzphetamine. Obesity [5B80-5B81] [28]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Polythiazide. Oedema [MG29] [21]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Fluphenazine and Levomethadyl Acetate. Opioid use disorder [6C43] [24]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Lofexidine. Opioid use disorder [6C43] [15]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Fluphenazine and Apraclonidine. Optic nerve disorder [9C40] [72]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Rucaparib. Ovarian cancer [2C73] [15]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Fluphenazine and Pentazocine. Pain [MG30-MG3Z] [18]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Fluphenazine and Dextropropoxyphene. Pain [MG30-MG3Z] [73]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Fluphenazine and Oxymorphone. Pain [MG30-MG3Z] [18]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Fluphenazine and Levorphanol. Pain [MG30-MG3Z] [18]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Fluphenazine and Dezocine. Pain [MG30-MG3Z] [18]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Fluphenazine and Nalbuphine. Pain [MG30-MG3Z] [18]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Fluphenazine when combined with Methamphetamine. Pain [MG30-MG3Z] [74]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Fluphenazine and Buprenorphine. Pain [MG30-MG3Z] [75]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Triclabendazole. Parasitic worm infestation [1F90] [15]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Fluphenazine and Safinamide. Parkinsonism [8A00] [38]
Pergolide DM14MAE Moderate Antagonize the effect of Fluphenazine when combined with Pergolide. Parkinsonism [8A00] [76]
Opicapone DM1BKA6 Moderate Additive CNS depression effects by the combination of Fluphenazine and Opicapone. Parkinsonism [8A00] [76]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Fluphenazine and Rasagiline. Parkinsonism [8A00] [38]
Biperiden DME78OA Moderate Antagonize the effect of Fluphenazine when combined with Biperiden. Parkinsonism [8A00] [44]
Levodopa DMN3E57 Moderate Antagonize the effect of Fluphenazine when combined with Levodopa. Parkinsonism [8A00] [76]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Pimavanserin. Parkinsonism [8A00] [77]
Bromocriptine DMVE3TK Moderate Additive CNS depression effects by the combination of Fluphenazine and Bromocriptine. Parkinsonism [8A00] [76]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Fluphenazine and Orphenadrine. Parkinsonism [8A00] [13]
Apomorphine DMX38HQ Moderate Antagonize the effect of Fluphenazine when combined with Apomorphine. Parkinsonism [8A00] [78]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Fluphenazine and Methylscopolamine. Peptic ulcer [DA61] [13]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Fluphenazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [79]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Fluphenazine and Lefamulin. Pneumonia [CA40] [80]
Hydrocortisone DMGEMB7 Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Hydrocortisone. Postoperative inflammation [1A00-CA43] [21]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Ritodrine. Preterm labour/delivery [JB00] [27]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Degarelix. Prostate cancer [2C82] [24]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Fluphenazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [81]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Nilutamide. Prostate cancer [2C82] [24]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Enzalutamide. Prostate cancer [2C82] [24]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Relugolix. Prostate cancer [2C82] [24]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Bicalutamide. Prostate cancer [2C82] [24]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Fluphenazine and Terazosin. Prostate hyperplasia [GA90] [22]
Tamsulosin DM5QF9V Moderate Additive hypotensive effects by the combination of Fluphenazine and Tamsulosin. Prostate hyperplasia [GA90] [22]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Fluphenazine and Silodosin. Prostate hyperplasia [GA90] [22]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Fluphenazine and Tolazoline. Pulmonary hypertension [BB01] [22]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Fluphenazine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [82]
Neupro DMHEAB1 Moderate Additive hypotensive effects by the combination of Fluphenazine and Neupro. Restless legs syndrome [7A80] [76]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Fluphenazine and Mesoridazine. Schizophrenia [6A20] [15]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Fluphenazine and Thioridazine. Schizophrenia [6A20] [83]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Fluphenazine and Aripiprazole. Schizophrenia [6A20] [13]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Fluphenazine and Iloperidone. Schizophrenia [6A20] [15]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Paliperidone. Schizophrenia [6A20] [15]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Fluphenazine and Perphenazine. Schizophrenia [6A20] [13]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Fluphenazine and Molindone. Schizophrenia [6A20] [13]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Fluphenazine and Thiothixene. Schizophrenia [6A20] [13]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Fluphenazine and Risperidone. Schizophrenia [6A20] [13]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Fluphenazine and Amisulpride. Schizophrenia [6A20] [84]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Asenapine. Schizophrenia [6A20] [15]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Fluphenazine and Pimozide. Schizophrenia [6A20] [24]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Fluphenazine and Fentanyl. Sensation disturbance [MB40] [18]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Fluphenazine and Sufentanil. Sensation disturbance [MB40] [18]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Vardenafil. Sexual dysfunction [HA00-HA01] [15]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Fluphenazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [15]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [24]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [15]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Pitolisant. Somnolence [MG42] [15]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [15]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Fluphenazine and Adenosine. Supraventricular tachyarrhythmia [BC81] [15]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Lenvatinib. Thyroid cancer [2D10] [15]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Fluphenazine and Cabozantinib. Thyroid cancer [2D10] [24]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Fluphenazine and Papaverine. Tonus and reflex abnormality [MB47] [22]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Fluphenazine and Tizanidine. Tonus and reflex abnormality [MB47] [85]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Astemizole. Vasomotor/allergic rhinitis [CA08] [15]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Fluphenazine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [13]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Fluphenazine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [19]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Fluphenazine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [13]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Fluphenazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [13]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Fluphenazine and Azatadine. Vasomotor/allergic rhinitis [CA08] [13]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Fluphenazine and Procainamide. Ventricular tachyarrhythmia [BC71] [15]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Propafenone. Ventricular tachyarrhythmia [BC71] [15]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Fluphenazine and Flecainide. Ventricular tachyarrhythmia [BC71] [15]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Fluphenazine and Amiodarone. Ventricular tachyarrhythmia [BC71] [15]
⏷ Show the Full List of 274 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 27 E00381 83511 Colorant
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium sulfate anhydrous E00303 24497 Desiccant; Diluent
Carmellose sodium E00625 Not Available Disintegrant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Sodium alginate E00671 Not Available Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 26 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Fluphenazine 5 mg tablet 5 mg Oral Tablet Oral
Fluphenazine 10 mg tablet 10 mg Oral Tablet Oral
Fluphenazine 2.5 mg tablet 2.5 mg Oral Tablet Oral
Fluphenazine Hydrochloride 10mg tablet 10mg Tablet Oral
Fluphenazine Hydrochloride 1mg tablet 1mg Tablet Oral
Fluphenazine Hydrochloride 2.5mg tablet 2.5mg Tablet Oral
Fluphenazine Hydrochloride 5mg tablet 5mg Tablet Oral
Fluphenazine 1 mg tablet 1 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 204).
2 Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother. 2015 Jan;59(1):742-4.
3 Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
10 Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
11 Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
12 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
13 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
14 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
15 Canadian Pharmacists Association.
16 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
17 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
18 Cerner Multum, Inc. "Canadian Product Information.".
19 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
20 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
21 Cerner Multum, Inc. "Australian Product Information.".
22 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
23 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
24 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
25 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
26 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
27 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
28 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
29 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
30 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
31 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
32 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
33 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
34 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
35 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
36 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
37 Nicholson SD "Extra pyramidal side effects associated with paroxetine." West Engl Med J 107 (1992): 90-1. [PMID: 1308691]
38 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
39 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
40 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
41 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
42 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
43 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
44 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
45 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
46 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
47 Multum Information Services, Inc. Expert Review Panel.
48 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
49 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
50 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
51 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
52 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
53 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
54 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
55 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
56 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
57 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
58 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
59 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
60 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
61 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
62 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
63 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
64 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
65 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
66 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
67 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
68 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
69 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
70 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
71 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
72 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
73 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
74 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
75 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
76 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
77 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
78 Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
79 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
80 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
81 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
82 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
83 Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
84 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
85 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.